In-Vitro Colorectal Cancer Screening Tests Market worth over $1.12bn by 2027

In-Vitro Colorectal Cancer Screening Tests Market size is set to surpass USD 1.12 billion by 2027, according to a new research report by Global Market Insights Inc.
 

Colorectal cancer is amongst the key factors responsible for cancer-related deaths globally, accounting for more than 1.8 million new cases and causing over 900,000 mortalities in 2018. The prevalence rate changes from country-to-country, with the prevalence around 3-times higher in developed countries as compared to emerging economies. The improvement in cancer therapeutics and the implementation of CRC screening programs by national agencies are expected to prove conducive for the market growth.
 

Adoption of CRC screening campaigns in communities enables early diagnosis of colonic neoplasms to reduce the treatment cost, morbidity, and mortality. These campaigns are intended to encourage the population to undergo CRC screening that is anticipated to drive the use of in-vitro colorectal cancer screening tests. Several countries including France, UK, Germany, Brazil, the U.S., and China among others have implemented opportunistic & population-based screening programs. In these screening programs, the government provides a well-developed and structured systematic process for inviting a certain group of individuals for screening.
 

Improvements in non-invasive testing approach in colorectal cancer screening to stimulate the in-vitro colorectal cancer screening tests market expansion

Researchers are increasingly pursuing the development of novel non-invasive tests as an alternative for invasive diagnostic approach. Invasive options including colonoscopy delivers high accuracy but features poor patient compliance owing to potential risk factors. Major CRC screening options include fecal occult blood tests (FOBT) that are widely used as a primary non-invasive screening tool. However, the limited efficacy, precision, and other drawbacks associated with the guaiac-based FOBT led to the development of immunochemical FOBTs (FIT). FIT has higher rates of acceptability and diagnostic precision that promotes analytical robustness.
 

Incorporation of biomarkers in stool and blood-based tests are observed as promising and increasingly preferred method among people. Research activities have further driven the development of multidimensional stool analysis screening approach for colorectal cancer detection. These tests include, DNA mutation, and DNA methylation among other in-vitro colorectal cancer screening tests. The results obtained from multidimensional analysis have promoted the improved detection rate of colorectal cancer and early diagnostics that aids in reducing the mortality rates.
 

Moreover, despite the supporting data, suggestions, and availability of multiple screening tests, a significant proportion of the U.S. population is non-complaint. For instance, the colorectal cancer screening compliance in the Nottingham trial was only 60% that indicates augmented need for compliance. As a result, several research activities are emphasizing on the development of a simple, non-invasive in-vitro colorectal cancer screening tests that facilitates high sensitivity. Development of non-invasive tests is slated to surge the compliance rate for patients, further driving the clinical outcomes.
 

High clinical accuracy and research activities for development of biomarker tests will spur the market progression

Get more details on this report - Request Free Sample PDF
 

The biomarker tests segment in the in-vitro colorectal cancer screening tests market is estimated to reach USD 107 million by 2027. This substantial industry growth is primarily attributed to high clinical accuracy and research activities for development of biomarker tests in CRC screening. Recent advances in genomics, proteomics, transcriptomics, and metabolomics have increased the number of potential biomarkers. This has resulted in improved comprehension related to the progression of CRC along with detection of molecular signatures. CRC tumors are heterogeneous owing to chromosomal instability (CIN), microsatellite instability (MSI), aberrant DNA methylation, and DNA repair defects. The current approach used for detection of CRC offer limited clinical success with a host of requirements and restrictions. As a result, the biomarkers are being increasingly preferred for early detection and diagnostics that leads to significant disease recovery. The augmented need for development of novel biomarker assays, optimal for early CRC detection has promoted numerous research activities concerning biomarker tests.
 

Browse key industry insights spread across 150 pages with 280 market data tables & 14 figures & charts from the report, “In-Vitro Colorectal Cancer Screening Tests Market Size By Test Type (Fecal Occult Blood Tests {Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test}, Biomarker Tests {Tumor M2-PK Stool Test, Transferrin Assays}, CRC DNA Screening Tests {Methylated Gene Testing, Panel DNA Tests}), By End-use (Hospitals, Clinics, Diagnostics Laboratories), COVID-19 Industry Analysis, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 – 2027” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/in-vitro-colorectal-cancer-screening-tests-market-report
 

Rising demand for colorectal cancer screening and development of non-invasive testing approach to foster the market revenue

The diagnostic laboratories segment dominated more than 54% of the in-vitro colorectal cancer screening tests market share in 2020 led by the growing demand for colorectal cancer screening and development of non-invasive testing approaches. Colorectal cancers occur sporadically and are generally characterized by carcinogenesis path that includes progressive accumulation of mutations. This prolonged development of CRC enables using screening for early detection and removal of premalignant lesions that reduces incidence and mortality. The 5-year survival rate for CRC patients with early disease diagnosis with surgical resection is around 90%. The high survival chances with early screening and detection of CRC is poised to promote the demand for in-vitro colorectal cancer screening tests.
 

The available gold standard screening test is the semi-invasive colonoscopy. Owing to invasive, expensive and significant risks involved, the colonoscopies are often reported to have poor patient compliance. Hence the development of affordable, non-invasive, precise, and easily measurable screening procedures such as CRC DNA screening and biomarkers are being increasingly used. This increased use is set to promote the patient compliance and is predicted to encourage the patients to implement CRC screening at diagnostic laboratories and other healthcare facilities. Additionally, cost-effective in-vitro colorectal cancer screening tests and use of advanced screening mechanism at diagnostic laboratories increments the patient preference.
 

Growing incidence of colorectal cancer in UK will expedite the market demand

UK in-vitro colorectal cancer screening tests market will account for over USD 38 million by 2027 due to the increasing prevalence of colorectal and lucrative government initiatives. High number of CRC cases and mortalities is expected to increase acceptance rate of in-vitro colorectal cancer screening tests, thereby promoting the market potential.
 

In order to curb the rising CRC mortality and promote early detection, the National Health Service (NHS) launched population-based screening in the country. This program provides free Bowel Cancer Screening Program (BCSP) for population aged 50 to 74 years. To increase precision, the screening guidelines are revised and have shifted to the use of fecal immunochemical test (FIT). In addition, the NHS also provides a one-off flexible sigmoidoscopy for people aged 55 years.
 

Players are focusing on implementation of strategic initiatives to boost the business operations

Some of the major companies operating in the market are Abbott Molecular, Epigenomics AG, Novigenix, Sysmex Corporation, Eiken Chemical, Quest Diagnostics, BioMarCare Technologies, Randox Laboratories, OncoCyte Corporation-Bio time, Exact Sciences Corporation, and Immunostics. These leaders are involved in acceptance of strategic initiatives such as collaborations, market penetration, and business expansion to gain competitive advantage in the industry.